Invited reviews and leading articles

Most recent publications

•	Theuretzbacher U, , Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O’Donnell J, Unemo M, Van Bambeke F, VanScoy B, Warn P, Werth BJ, Franceschi F, Alirol E: Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea-challenges and opportunities. Clin Microbiol Infect. 2020;26(12):1630-1635
•	Theuretzbacher U: Dual-mechanism antibiotics Nat Microbiol. 2020 Aug;5(8):984-985.
•	Paul M, Harbarth S, Huttner A, Thwaites GE, Theuretzbacher U, Bonten MJM, Leibovici L: Investigator-initiated randomized controlled trials in infectious diseases: better value for money for registration trials of new antimicrobials. Clin Infect Dis. 2020 Jul 3
•	Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group: Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes Clin Microbiol Infect. 2020 Apr 3
•	Kristoffersson AN, Rognås V, Brill MJE, Dishon-Benattar Y, Durante-Mangoni E, Daitch V, Skiada A, Lellouche J, Nutman A, Kotsaki A, Andini R, Eliakim-Raz N, Bitterman R, Antoniadou A, Karlsson MO, Theuretzbacher U, Leibovici L, Daikos GL, Mouton JW, Carmeli Y, Paul M, Friberg LE.: Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Clin Microbiol Infect. 2020 Mar 22
•	Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH,  Tacconelli E, Thwaites GE: Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol. 2020 May;18(5):286-298
•	Theuretzbacher U, Outterson K, Engels A, Karlén A: The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020 May;18(5):275-285.
•	Lepore C, Silver L, Theuretzbacher U, Thomas J, Visi D. The small-molecule antibiotics pipeline: 2014-2018. Nat Rev Drug Discov. 2019 Sep;18(10):739.
•	Theuretzbacher U, Piddock LJV: Non-traditional Antibacterial Therapeutic Options and Challenges. Cell Host Microbe. 2019 Jul 10;26(1):61-72.
•	Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S. Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infect Dis. 2019 Feb;19(2):e40-e50 Tables

•	Theuretzbacher U, Paul M. Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin. Clin Microbiol Infect. 2018 Dec;24(12):1231-1233.

•	Nation RL, Theuretzbacher U, Tsuji BT; International Society of Anti-Infective Pharmacology (ISAP). Concentration-dependent plasma protein binding: Expect the unexpected. Eur J Pharm Sci. 2018 Sep 15;122:341-346

•

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018 May 1;319(17):1781-1789.

•	Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L. Colistin versus colistin plus meropenem for severe infections Authors’ reply. Lancet Infect Dis. 2018 May;18(5):495-496.

•	Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabuschi F, Røttingen JA. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. J Pharm Policy Pract. 2018 Apr 5;11:8.

•	Tängdén T, Pulcini C, Aagaard H, Balasegaram M, Hara GL, Nathwani D, Sharland M, Theuretzbacher U, Cars O. Unavailability of old antibiotics threatens effective treatment for common bacterial infections. Lancet Infect Dis. 2018 Mar;18(3):242-244. Erratum in: Lancet Infect Dis. 2018 Feb 28

•

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391-400.

•

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318-327

•	Paul M, Theuretzbacher U. β-lactam prolonged infusion: it’s time to implement! Lancet Infect Dis. 2018 Jan;18(1):13-14.

•	Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need.  Curr Opin Microbiol. 2017 Oct;39:106-112.

•	Theuretzbacher U, Savic M, Årdal C, Outterson K. Innovation in the preclinical antibiotic pipeline. Nat Rev Drug Discov. 2017 Nov;16(11):744-745.

•	Theuretzbacher U. New drugs – will they solve the problem of resistance to antibiotics? Clin Microbiol Infect. 2017 Oct;23(10):695-696 (Editorial)
•	Theuretzbacher U. Antibiotic innovation for future public health needs. Clin Microbiol Infect. 2017 Oct;23(10):713-717
•	Theuretzbacher U, Årdal C, Harbarth S. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infect Dis Rep. 2017 Mar 30;9(1):6836.
•	Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017 Jul;43(7):1021-1032
•	Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics: Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents. 2017 Jan;49(1):98-101
•	Ursula Theuretzbacher: Antibacterial innovation in European SMEs. Nature Reviews Drug Discovery 2016, 15:812–813
•	Huttner A, Leibovici L, Theuretzbacher U, Huttner B, Paul M: Closing the evidence gap in infectious disease: point-of-care randomization and informed consent. Clin Microbiol Infect. 2017 Feb;23(2):73-7
•	U. Theuretzbacher: Optimizing the Use of Old Antibiotics—A Global Health Agenda. APUA Newsletter 2016, 34(2)
•	Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open. 2016 Apr 20;6(4):e009956.
•	Theuretzbacher U, Paul M: Editorial. Revival of old antibiotics: structuring the re-development process to optimize usage. Clin Microbiol Infect. 2015 2015 Oct;21(10):878-80.
•	Muller AE, Theuretzbacher U, Mouton JW: Use of old antibiotics now and in the future from a PK/PD perspective. Clin Microbiol Infect. 2015 Oct;21(10):881-5.
•	Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW: Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64.
•	Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G: Reviving old antibiotics. J Antimicrob Chemother. 2015 Aug;70(8):2177-81.
•	Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL: In memoriam: William A. Craig. Antimicrob Agents Chemother. 2015 Jun;59(6):2971.
•	Harbarth S, Theuretzbacher U, Hackett J; on behalf of the DRIVE-AB consortium: Antibiotic research and development: business as usual? J Antimicrob Chemother. 2015 Jun;70(6):1604-7
•	Ursula Theuretzbacher: Recent FDA Antibiotic Approvals: Good News and Bad News. CDDEP blog 12 Mar 2015
•	Nation R, Li J, Cars O, Couet W, Dudley M, Kaye K, Mouton J, Paterson D, Tam V, Theuretzbacher U, Tsuji B, Turnidge J. Framework for optimising the clinical use of colistin and polymyxin B: The Prato Polymyxin Consensus. Lancet Infectious Diseases 2015 Feb;15(2):225-34
•	Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014 Sep;69(9):2305-9.
•	JA Roberts, MHA Aziz, J Lipman, JW Mouton, AA Vinks, TW Felton, WW Hope, A Farkas, MN Neely, JJ Schentag, G Drusan, OR Frey, U Theuretzbacher, JL Kuti. On behalf of The International Society of Anti-Infective Pharmacology (ISAP) and the PK/PD Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498-509
•	U. Theuretzbacher: Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 2014, 69(7):1987-92
•	Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 58(1):139-41
•	Kaier K, Lambert ML, Frank UK, Vach W, Wolkewitz M, Tacconelli E, Rello J, Theuretzbacher U, Martin M. Impact of availability of guidelines and active surveillance in reducing the incidence of ventilator-associated pneumonia in Europe and worldwide. BMC Infect Dis. 2014, 12;14(1):199
•	U. Theuretzbacher: Global antibacterial resistance: The never-ending story. J Global Antimicrob Resistance 2013, 1(2):63-69
•	Tambyah PA, Hara GL, Daikos GL, Falagas ME, Mazzei T, Mouton JW, Novelli A, Chen B, Wang M, Ko W, Li T, Fan X, Theuretzbacher U. Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. J Global Antimicrob Resistance 2013;1(3):117-122
•	U. Theuretzbacher: Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis. 2012;54(12):1785-92
•	U. Theuretzbacher: Accelerating resistance, inadequate antibacterial pipelines and international responses. Int J Antimicrob Agents. 2012;39(4):295-9
•	Theuretzbacher U, Mouton JW. (Editorial) Update on antibacterial and antifungal drugs – can we master the resistance crisis? Curr Opin Pharmacol. 2011, 11(5):429-432
•	Theuretzbacher Ursula: Resistance drives antibacterial drug development. Curr Opin Pharmacol. 2011, 11(5):433-438
•	Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. Protein binding – do we ever learn? Antimicrob Agents Chemother. 2011, 55(7):3067-74
•	Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The Effect of Critical Illness on Drug Distribution. Curr Pharm Biotechnol. 2011, 12(12):2030-2036.
•	Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, Macgowan A, Theuretzbacher U, Turnidge J.: Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat. 2011, 14(2):107-17
•	Y. Li, U. Theuretzbacher, CJ. Clancy, MH. Nguyen, H. Derendorf: Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clin Pharmacokin 2010, 49 (6) 379-396
•	U. Theuretzbacher: Antibiotics: derivative drugs, novel compounds and the need for effective resistance strategies. Future Microbiol. 2009 Dec;4:1243-7
•	U. Theuretzbacher: Antibiotic innovation on the horizon? APUA news 2009, 27, 1 & 2
•	U. Theuretzbacher: Future antibiotics scenarios: is the tide starting to turn? International Journal of Antimicrobial Agents 2009; 34:15-20
•	J. Mouton, U. Theuretzbacher, W. Craig, P. Tulkens, H. Derendorf, O. Cars: Tissue-concentrations: Do we ever learn? J Antimicrob Chemother. 2008;61(2):235-7
•	U. Theuretzbacher: Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? (Abstract, page 1) Current Opinion in Pharmacology 2007; 7/5:498-504
•	U. Theuretzbacher: Antimicrobial Resistance–2006 Annual Conference. Science-prevention-control. IDrugs. 2006 Sep;9(9):622-4
•	U. Theuretzbacher: The opponent, we were unable to defeat. Beta-lactamases. Pharm.unserer Zeit 5/2006 (35): 416-21 Page 1
•	U. Theuretzbacher, F. Ihle, H. Derendorf: Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. Clin Pharmacokinet 2006; 45 (7): 649-663 (Abstract)
•	U. Theuretzbacher, J. Toney: Nature’s clarion call of antibacterial resistance: are we listening? Curr Opin Investig Drugs. 2006 Feb;7(2):158-66. (Abstract)
•	U. Theuretzbacher: Pharmacokinetics/Phamacodynamics of Echinocandins. European Journal of Clinical Microbiology and Infectious Diseases 2004, published online: 14 October 2004
•	U. Theuretzbacher: Beta-Lactamases and Beta-Lactamase Inhibitors – an update. Chemotherapie-Journal 2004 (13) 5
•	U. Theuretzbacher: Cefpodoxim bei Atemwegsinfektionen. Antibiotika Monitor 2000, (16) 4
•	U. Theuretzbacher: ß-Laktamasen und ß-Laktamase-Inhibitoren. Chemotherapie-Journal 1998 (7) 4: 136-142
•	U. Theuretzbacher: Erreger der Otitis media. Chemotherapie-Journal 1997 (6) Suppl. 16: 17-14
•	U. Theuretzbacher: Neue orale Cephalosporine. Antibiotika Monitor 1997 (12) 2: 31-37
•	U. Theuretzbacher: Therapie der Wahl bei eitriger Angina. Arzneimittelpraxis 1997 (27) 1
•	F. Vogel, U. Theuretzbacher: Antibiotikatherapie auf der Intensivstation. Intensivmed. 1997 (34): 14-23
•	U. Theuretzbacher: Antibiotikatherapie der A-Streptokokken-Pharyngotonsillitis. Antibiotika Monitor 1997 (12) 2: 26-30
•	U. Theuretzbacher: Alte und neue Infektionskrankheiten. 1996 (4) Medizin im Dialog
•	U. Theuretzbacher: Makrolide. 1995, (11) 3: 26-37
•	U. Theuretzbacher: Resistenzprobleme im Krankenhaus. Österreichische Krankenhaus Pharmazie. 1995 (9), 4: 8-10
•	U. Theuretzbacher: Penicillin-resistente Pneumokokken. 1994, (10) 3: 76-81
	F. Vogel, U. Theuretzbacher: Makrolide. MMW 1994 (136):771-776
Articles, abstracts
•	Margret Seewald, Ursula Theuretzbacher: Schneller Erregernachweis bei Vaginalinfektionen. Geburtshilfe und Frauenheilkunde 2001, 61: 1-4
•	M. Seewald, U. Theuretzbacher: In-vitro activity of piperacillin alone and combined with sulbactam or tazobactam against hospital-derived pathogens. ECCMID 2000, abstract
•	M. Seewald, U. Theuretzbacher: Evaluation of BD Affirm VP III microbial identification test for three vaginal pathogens. Third symposium on molecular diagnostics in laboratory medicine, Graz, 2000, abstract
•	Kurt Naber, Ursula Theuretzbacher, G. Moneva-Koucheva, H. Staß: Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. European Journal of Microbiology and Infectious Diseases 1999, 18: 783-789
•	F. Allerberger, I. Klare, U. Theuretzbacher: In vitro-Aktivität von Fosfomycin gegen vancomycinresistente Enterokokken. Antibiotika Monitor 1998, XIV/5: 74-79

•	Kurt Naber, Ursula Theuretzbacher, Martina Kinzig, Orlin Savov, Fritz Sörgel: Urinary excretion and bactericidal activity following a single oral dose of 400mg fleroxacin versus 800mg pefloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 1998, 42: 1659-1665
•	A. Georgopoulos, U. Theuretzbacher, A. Buxbaum, U. Straschil, W. Graninger: Susceptibility of community-acquired lower respiratory tract pathogens: the Alexander Project in Austria. International Conference on the Macrolides, Azalides, Streptogramins and Ketolides IV 1998, abstract 11.25
•	S. F. Egger, V. Huber-Spitzy, U. Theuretzbacher, M. Schiffbänker und G. Grabner: Reduction of risk-factors for postoperative infections: prospective study on 200 cataract-patients Spektrum der Augenheilkunde, 1994, 8: 265-267

Numerous articles appeared in medical weekly journals and newspapers.